ONCO Onconetix, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1782107 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY-51.3%
TTM net income YoY76.9%
TTM EPS YoY216.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.4%
Operating margin-2,525.0%
Net margin-1,578.8%
FCF margin—
EBITDA margin-2,522.7%
Returns
ROE-105.2%
ROA-57.4%
ROIC (approx.)-195.9%
Asset turnover0.04x
Leverage & solvency
Liabilities / assets18.0%
Debt / equity0.00x
Current ratio2.21x
Interest coverage-52.44x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $815,371 | $2.52M |
| Cost of revenue | $182,458 | $1.47M |
| Gross profit | $632,913 | $1.06M |
| R&D expense | — | $154,359 |
| SG&A expense | $7.04M | $11.23M |
| Operating income | -$17.86M | -$56.49M |
| Interest expense | $751,005 | $873,433 |
| Pretax income | -$14.03M | -$59.74M |
| Income tax | $525 | -$1.05M |
| Net income | -$14.03M | -$58.69M |
| EBITDA | -$17.84M | -$55.76M |
| EPS (basic) | -16.56 | -1,823.39 |
| EPS (diluted) | -16.56 | -1,823.39 |
| Weighted avg. shares (diluted) | 937,690 | 32,301 |
| Banking | ||
| Deposits | — | $3.50M |
| Balance sheet | ||
| Cash & equivalents | $5.22M | $646,500 |
| Receivables | $296,866 | $25,717 |
| Inventory | $149,961 | $64,079 |
| Current assets | $6.07M | $950,267 |
| PP&E, net | $37,085 | $62,896 |
| Goodwill | $18.55M | $18.55M |
| Total assets | $24.93M | $28.18M |
| Current liabilities | $9.14M | $18.29M |
| Total liabilities | $9.16M | $18.57M |
| Shareholders' equity | $15.76M | $8.54M |
| Shares outstanding | 31,198 | 138,270 |
| Cash flow statement | ||
| Operating cash flow | -$9.68M | -$10.50M |
| Capital expenditure | — | $28,471 |
| Free cash flow | — | -$10.52M |
| Investing cash flow | — | -$28,471 |
| Financing cash flow | $14.45M | $6.74M |
| Depreciation & amortization | $15,170 | $731,345 |
| Stock-based compensation | $74,267 | $438,653 |
Free plan shows the latest 2 periods; Pro shows all 5 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.